Serami Murakami

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka et al. · Cancers · 2021 · 42 citations · Full text

Medicine, Oncology, Pharmacology +14

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka et al. · Liver Cancer · 2022 · 18 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +13

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

Shigeki Yano, Tomokazu Kawaoka, Yusuke Johira et al. · Medicine · 2021 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma

Kei Amioka, Tomokazu Kawaoka, Masanari Kosaka et al. · Cancers · 2022 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17